

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1202 daily bars · split adjusted
Current price $0.163
Latest analyst grade actions
Daily · Wilder smoothing
Classic floor pivots from 2026-08-10
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 41.56 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 81.48 | Oscillator | Sell |
| Williams %R (14) | -22.22 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.05 (Hist 0.02) | Oscillator | Buy |
| Average Directional Index (14) | 39.45 (+DI 15.5 / -DI 19.9) | Trend | Strong Sell |
| EMA 20 | 0.15 | MA | Strong Sell |
| SMA 20 | 0.11 | MA | Strong Buy |
| EMA 50 | 0.27 | MA | Strong Sell |
| SMA 50 | 0.30 | MA | Strong Sell |
| SMA 200 | 1.21 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 14, 26 | Shorten Richard Lee Jr. | director | A-Award | 100,000 @ $0.15 | $15.00K |
| Sep 14, 26 | Larsen Todd | director | A-Award | 100,000 @ $0.15 | $15.00K |
| Sep 14, 26 | Lee Lok | director | A-Award | 100,000 @ $0.15 | $15.00K |
| Sep 3, 26 | Lee Lok | director: | 0 | — | |
| Jun 11, 26 | Shorten Richard Lee Jr. | director | 641,426 @ $1.05 | $673.5K | |
| Jun 11, 26 | Shorten Richard Lee Jr. | director | 550,000 @ $0.38 | $209.0K | |
| Jun 11, 26 | Shorten Richard Lee Jr. | director | 1,151,810 @ $0.0001 | $115 | |
| Oct 3, 25 | Shorten Richard Lee Jr. | director | 1,310,242 @ $3.82 | $5.01M |
Stock news · updated daily
Sagimet Biosciences (NASDAQ: SGMT - Get Free Report) and Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation. Insider and Institutional Ownership 87.9% of
STONY BROOK, N.Y.--(BUSINESS WIRE)--BNB Plus Corp. (OTCQB: BNBX) ("BNBX" or the "Company") today announced that the Company will transition from its current strategy as a digital asset treasury company focused exclusively on the BNB Chain ecosystem into an operating company focused on the deployment of infrastructure necessary for financial institutions and enterprises to adopt, operate, and utilize emerging open network technologies, including blockchain and agentic AI. As blockchain networks.
Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and Myriad Genetics (NASDAQ: MYGN - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends. Profitability This table compares Applied Dna
Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and Neurogene (NASDAQ: NGNE - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends. Analyst Ratings This is a summary of
STONY BROOK, N.Y.--(BUSINESS WIRE)--BNB Plus Corp. (OTCQB: BNBX) ("BNB Plus" or the "Company") today announced the appointment of three new members to its Board of Directors, identified as part of the Company's ongoing strategic review process. The incoming members of the Board bring extensive experience across corporate restructuring, institutional finance, digital assets, and the network infrastructure at the core of modern and decentralized compute networks. New Board members include: Richar.
STONY BROOK, N.Y.--(BUSINESS WIRE)--BNB Plus Corp. (OTCQB: BNBX) ("BNB Plus" or the "Company") today announced that, in furtherance of its ongoing strategic review, it has reached a mutual agreement with Cypress Management, LLC and its affiliates to conclude their advisory and asset management arrangement, transitioning execution of the Company's BNB treasury strategy fully in-house. Clay Shorrock, President and CEO, noted, "Cypress has been a valued, professional partner throughout our relatio.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| May 15, 2026 | — | -0.68 | — | $1.02M |
| Feb 12, 2026 | — | -2.08 | — | $565.4K |
| Dec 22, 2025 | -22.50 | -3.17 | Beat 85.9% | $199.4K |
| Aug 14, 2025 | -37.50 | 34.00 | Beat 190.7% | $304.4K |
| May 15, 2025 | -0.45 | -2.30 | Miss -411.7% | $983.4K |
| Feb 13, 2025 | -2.44 | -4.20 | Miss -72.3% | $1.20M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Apr 29, 2026 | 2026-04-29 20:10:24 | View |
| 4 | Mar 31, 2026 | 2026-03-31 20:09:34 | View |
| 4 | Mar 31, 2026 | 2026-03-31 20:08:21 | View |
| 4 | Mar 31, 2026 | 2026-03-31 20:07:36 | View |
| 4 | Mar 31, 2026 | 2026-03-31 20:06:52 | View |
| 4 | Mar 31, 2026 | 2026-03-31 20:06:14 | View |
| 4 | Mar 31, 2026 | 2026-03-31 20:05:27 | View |
| SC 13D | Mar 24, 2026 | 2026-03-25 00:09:48 | View |
| DEF 14A | Mar 24, 2026 | 2026-03-24 20:15:13 | View |
| 8-K | Mar 24, 2026 | 2026-03-24 20:06:00 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | BNBX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.0x | -8.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.0x | EPS est. -82.50 | Discount |
| Price / Book | 0.1x | 15.0x | Discount |
| Price / Sales | 0.6x | 9.0x | Discount |
| EV / EBITDA | -0.0x | -9.2x | Discount |
| Return on equity | -337.1% | — | Weak |
| Gross margin | 43.5% | 37.6% | Above hist. |
| Debt / Equity | 0.00 | 0.08 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -49.27 | Distress |
Discounted cash flow model